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Oxidative stress (OS) and mitochondrial dysfunction are implicated in neurodegenerative disease, sug-
gesting that antioxidant defence systems are critical for cell survival in the central nervous system (CNS).
Oxidation resistance 1 (OXR1) can protect against OS in cellular and mouse models of amyotrophic lateral
sclerosis (ALS) when over-expressed, whereas deletion of Oxr1 in mice causes neurodegeneration. OXR1
has emerged therefore as an essential antioxidant protein that controls the susceptibility of neurons to
OS. It has been suggested that OXR1 is localised to mitochondria, yet the functional signiﬁcance of this
has not been investigated in the context of neuronal cell death. In order to characterise the role of Oxr1 in
mitochondria, we investigated its sub-mitochondrial localisation and demonstrate that speciﬁc isoforms
are associated with the outer mitochondrial membrane, while the full-length Oxr1 protein is pre-
dominately cytoplasmic. Interestingly, cytoplamsic over-expression of these mitochondrially-localised
isoforms was still able to protect against OS-induced cell death and prevent rotenone-induced mi-
tochondrial morphological changes. To study the consequences of Oxr1 deletion in vivo, we utilised the
bella ataxic mouse mutant. We were unable to identify defects in mitochondrial metabolism in primary
cerebellar granule cells (GCs) from bellamice, however a reduction in mitochondrial length was observed
in mutant GCs compared to those from wild-type. Furthermore, screening a panel of proteins that reg-
ulate mitochondrial morphology in bella GCs revealed de-regulation of phospho-Drp1(Ser616), a key
mitochondrial ﬁssion regulatory factor. Our data provide new insights into the function of Oxr1, revealing
that speciﬁc isoforms of this novel antioxidant protein are associated with mitochondria and that the
modulation of mitochondrial morphology may be an important feature of its protective function. These
results have important implications for the potential use of OXR1 in future antioxidant therapies.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Mitochondrial impairment is a common feature in aging and
neurodegenerative diseases [1]. Mitochondria generate reactive
oxygen species (ROS) as normal by-products of respiration and the
accumulation of ROS can induce oxidative stress (OS) causing da-
mage to critical cellular components such as proteins, lipids and
DNA [2]. Furthermore, mitochondrial DNA (mtDNA) damage ac-
cumulates with age, triggering the impairment of respiration and
ultimately the production of ROS [3]. Mitochondria are also highly
dynamic and constantly undergo fusion and ﬁssion in order to
maintain efﬁcient energy production and mitigate stress; defects
in these speciﬁc processes can also lead to OS and have been as-
sociated with Alzheimer's, Parkinson's and Huntington's disease
[4]. However, whether OS is the primary cause or merely ar Inc. This is an open access article
iver).secondary consequence of neurodegeneration still remains unclear
[5], and the potential role that OS plays at the presymptomatic
stage of neurodegenerative disease requires further investigation.
In recent years, factors that are known to counteract OS have been
harnessed to alleviate mitochondrial dysfunction in neurodegen-
erative disease models with mixed success [6]; thus characterising
new antioxidant pathways is an important strategy for the iden-
tiﬁcation of novel therapeutic targets.
The protein oxidation resistance 1 (OXR1) was ﬁrst identiﬁed
during a screen for genes that were protective against OS [7]. OXR1
has orthologues present in all eukaryotic organisms from yeast to
humans and it has been demonstrated that the antioxidant
properties of this protein are conserved throughout evolution
[7,8]; Oxr1 deletion in Saccharomyces cerevisiae increases sensi-
tivity to hydrogen peroxide (H2O2) damage [7] and the mouse Oxr1
deletion mutant (bella) displays progressive ataxia, a shortened
lifespan and cerebellar neurodegeneration [9]. More recently,
knockdown of OXR1 in mammalian cells was also found to reduceunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Signiﬁcantly, increased expression of OXR1 has been shown con-
sistently to be protective both in vitro and in vivo. For example, in
Caenorhabditis elegans, over-expression protects cells against OS
and aging [11], while over-expression of Oxr1 from Bombyx mori
signiﬁcantly extends the life-span of Drosophila melanogaster [12].
We have also demonstrated that an Oxr1 transgene can delay
neurodegeneration in an mouse model of amyotrophic lateral
sclerosis (ALS), [13] and over-expressing Oxr1 in mammalian cells
can alleviate cellular abnormalities caused by pathogenic ALS-as-
sociated mutations [13]. Taken together, this evidence suggests
that OXR1 plays a key protective role against OS.
OXR1 contains a conserved TBC/LysM-associated domain-con-
taining (TLDc) C-terminal domain that is also present in a small
family of proteins containing TBC1 domain family, member 24
(TBC1D24) and nuclear receptor coactivator 7 (NCOA7). Sig-
niﬁcantly, mutations in the TLDc domain of TBC1D24 are asso-
ciated with Familial Infantile Myoclonic Epilepsy (FIME) and Pro-
gressive Myoclonic Epilepsy (PME) [14,15]. It has also been shown
that short isoforms of Oxr1-containing predominantly the TLDc
domain - are sufﬁcient to protect cells against OS [9,16]. The
function of the TLDc domain was proposed initially to be enzy-
matic [17], yet its crystal structure shows a conformation distinct
from any other known enzymatic structures [18]. In addition, al-
though there is evidence that Oxr1 is localised to mitochondria in
mammalian and yeast cells [9,19], the function of Oxr1 or the TLDc
domain itself remains unknown. Therefore, further understanding
of Oxr1 in the context of mitochondrial structure and metabolism
may provide valuable clues regarding the function of the protein.
The aim of this study was to determine the functional sig-
niﬁcance of the sub-cellular and sub-mitochondrial localisation of
Oxr1 in the mouse and evaluate the potential effect of Oxr1 de-
letion on mitochondrial morphology and metabolism. Our data
show that Oxr1 expression in mitochondria is isoform-speciﬁc,
and that levels of the protein can inﬂuence aspects of mitochon-
drial structure as well as sensitivity to OS.2. Material and methods
2.1. Animals
All procedures relating to animal use have been carried out
according to UK Home Ofﬁce regulations and have been approved
by the University of Oxford Ethical Review Panel. The bella mu-
tation has been described previously as a genomic deletion of
approximately 190 kb that spans the entire Oxr1 locus, thus no
protein-coding exons of the full-length isoform (Accession number
NM_130885 / Oxr1-FL) or any of the shorter isoforms remain [9].
Homozygous bella mutants display progressive ataxia from post-
natal day (P)18–20 and disease end-stage, when animals are un-
able to right themselves, occurs at P22-P24. Animals are main-
tained on a C3H/HeH background from heterozygous matings and
littermate controls were used throughout.
2.2. Mitochondria isolation
The puriﬁcation of mitochondria from tissues or eukaryotic
cells was performed as per the manufacturer's instructions
(Qiagen).
2.3. Mitochondria sub-fractionation
Mitochondria were sub-fractionated by following a swelling-
shrinking procedure originally described by Hovius et al. [20] with
minor modiﬁcations. Isolated mitochondria from tissues weresuspended in buffer A (10 μM KH2PO4, pH 7.4) and placed on ice
for 20 min, then 1 volume of buffer B (32% sucrose, 30% glycerol,
and 10 mM MgCl2, pH 7.4) was added. The mixture was sonicated
6 times for 5 s using a Soniprep 150 sonicator (Jencons-PLS) then
centrifuged at 10,000g at 4 °C for 10 min. The pellet was re-sus-
pended in buffer A (10 μM KH2PO4, pH 7.4) and incubated on ice
for 20 min. Then, 1 volume of buffer B (32% sucrose, 30% glycerol,
and 10 mM MgCl2, pH 7.4) was added followed by further soni-
cation as above. The re-suspended pellet was centrifuged at
150,000g at 4 °C for 1 h using a Ti70 rotor (Beckman Coulter). Four
fractions were obtained corresponding to the outer membrane
(OM), the intermembrane space (IMS), the inner membrane (IM)
and the matrix (MX). The IMS and MX supernatants were con-
centrated using Ultracel-10K ﬁlters (Millipore). The identity of the
fractions was conﬁrmed by western blotting using markers spe-
ciﬁc mitochondrial compartments: VDAC (1:1000, Cell Signaling)
for OM, cytochrome c (1:1000, Cell Signaling) for IMS, cytochrome
c oxidase subunit IV (COX IV) (1:2000, Abcam) for IM and HSP-60
(1:1000, Cell Signaling) for MX. The anti-Oxr1 antibody was used
at 1:500 [9].
2.4. Trypsin susceptibility assay
The trypsin susceptibility assay was carried out as described by
Choo et al. [21] with minor modiﬁcations. Brieﬂy, increasing
concentrations of trypsin (0, 10, 100 and 500 mg/ml) was used to
treat isolated mitochondria (150 mg) on ice for 30 min. The mi-
tochondria were then centrifuged at 6000g at 4 °C for 10 min for
separation from the trypsin solution. Samples were then subjected
to western blotting with the Oxr1 antibody and mitochondrial
markers as indicted above.
2.5. Plasmids
The full-length (NM_130885/Oxr1-FL) or the short mouse Oxr1
isoform (based on NM_001130164 with an additional 28 amino-
acid second exon that is shared with Oxr1-FL/Oxr1-C) was cloned
into pCMV/myc/cyto (Invitrogen) to generate the myc-tagged cy-
toplasmic Oxr1 constructs Oxr1-FL-cyto and Oxr1-C-Cyto, re-
spectively. Oxr1-C was targeted to the mitochondria by cloning
into pCMV/myc/mito containing an N-terminal mitochondrial
targeting signal (MSVLTPLLLRGLTGSARRLPVPRAKIHSL) (Invitro-
gen) [22] to generate Oxr1-C-Mito. Upon translocation into the
mitochondria, the targeting sequence is removed at the N-termi-
nus of Oxr1.
2.6. Cell culture and transfection
Cervix epitheloid carcinoma (HeLa) and Neuro2a (N2a) cells
were grown routinely in ﬂasks or plates containing DMEM (Life
Technologies) supplemented with 10% Foetal bovine serum (FBS)
and 1% Penicillin/Streptomycin (Life Technologies) in a humidiﬁed
incubator at 37 °C in 5% CO2. Culturing mouse primary cerebellar
granule neurons was conducted as previously described [23].
Transfection was conducted using FuGENE 6 reagent (Promega) as
per the manufacturer's instructions.
2.7. Cell death assay
HeLa cells expressing Oxr1-myc with cytoplasmic (Oxr1-C-
Cyto) and mitochondrial (Oxr1-C-Mito) signals were exposed to
250 μmH2O2 for 4 h. Cell apoptosis was observed by labelling cells
with an anti-cleaved Caspase-3 (Asp175) antibody (1:1400, Cell
Signaling). For quantiﬁcation, ﬁve 20 microscopic ﬁelds were
randomly selected for each coverslip.
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To quantify COX IV-stained mitochondria in cultured primary
GCs, confocal images (10241024 pixels) were acquired using by
a Leica TCS SP5II confocal microscope (63 oil objective; scan
speed: 200 Hz) with LAS AF software. Images were then exported
and processed with NIH ImageJ FIJI software; the entire range of
grey values (0–255) was covered by contrast optimisation, then,
binary images of mitochondria were generated. The number of
mitochondria per cell and the average area of a mitochondrion
were subsequently evaluated using the particle analysing tool (size
in pixel units: 10-inﬁnity; circularity: 0.00–1.00).
2.9. SDS-PAGE analysis
Protein samples were separated by 12% or 16% SDS poly-
acrylamide (SDS-PAGE) gel electrophoresis followed by transfer-
ring to PVDF membranes (GE Healthcare). Membranes were in-
cubated in blocking solution containing 5% skimmed milk in TBST
(10 mM Tris–HCl pH 7.6, 150 mM NaCl and 0.1% Tween 20) for 1 h
prior to incubation with primary antibodies for either 1 h at room
temperature or overnight at 4 °C. After washing with TBST three
times, membranes were incubated with appropriate HRP-con-
jugated secondary antibodies (1:5000, GE Healthcare). Blots were
then developed with the ECL kit (GE Healthcare). Primary anti-
bodies were: rabbit anti-TOM20 (1:200, Santa Cruz), rabbit anti-
VDAC (1:1000, Cell Signaling), rabbit anti-cytochrome-c (1:1000,
Cell Signaling), rabbit anti-COX IV (1:2000, Abcam), rabbit anti-
HSP-60 (1:1000, Cell Signaling), mouse MitoProﬁle total OXPHOS
rodent WB antibody cocktail (1:250, Abcam), mouse anti-c-Myc
(1:5000, Sigma-Aldrich), rabbit anti-GAPDH (1:5000, Sigma-Al-
drich; or 1:1000, Cambridge Bioscience), mouse anti-Mfn1 (1:250,
Abcam), mouse anti-Mfn2 (1:250, Abcam), rabbit anti-Fis1(1:500,
Santa Cruz), rabbit anti-Drp1 (1:1000, Cell Signaling), rabbit anti-
phospho-Drp1 (Ser616) (1:1000, Cell Signaling), goat anti-OPA1
(1:500, Santa Cruz).
2.10. BN-PAGE analysis
Blue Native-PAGE analysis was performed using the NovexH
Bis-Tris Gel system (Life Technologies) as per the manufacturer's
protocol: isolated mitochondrial samples were lysed in sample
buffer containing 2.5% n-dodecyl-b-Dmaltoside (DTT) made using
the Native PAGE Sample Prep Kit (Invitrogen). The samples were
subjected to centrifugation at 17,000g at 4 °C for 30 min and loa-
ded (50 mg) onto a native polyacrylamide Novex 3–12% Bis-Tris Gel
(Life Technologies). Electrophoresis (PAGE) was then carried out at
4 °C. After electrophoresis, proteins were transferred to a PVDF
membrane (GE Healthcare) and ﬁxed with 8% acetic acid and
blocked with 5% skimmed milk in TBST for 1 h. Mitochondrial
complexes were probed with monoclonal anti-OxPhos Complex
Kit (1:250, Invitrogen).
2.11. Immunostaining
Cells (HeLa and primary GCs) on coverslips were washed with
PBS followed by incubation in 4% PFA at room temperature for 20–
30 min. Coverslips were washed in PBS three times and permea-
bilised with 0.1% Trition X-100 prior to incubation in blocking
solution containing 5% bovine serum albumin (Sigma-Aldrich) and
5% goat serum (Vectorlabs) for 1 h at room temperature. After
blocking, coverslips were incubated with primary antibodies for
either 1 h at room temperature or overnight at 4 °C. The coverslips
were then washed three times in PBS and incubated with sec-
ondary antibodies for 2 h (Alexa Fluor, 1:500, Thermoﬁsher). After
incubation, coverslips were washed again three times in PBS andmounted in mounting medium with DAPI (Vector Laboratories).
Primary antibodies were: mouse anti-c-Myc (1:100, Sigma-Al-
drich), rabbit anti-cleaved caspase-3 (Asp175) (1:1400, Cell Sig-
naling), rabbit anti-GABA(A) receptor alpha 6 subunit (1:100,
Merck Millipore) and rabbit anti-COX IV (1:1000, Abcam).
2.12. Mitochondrial DNA damage test
Mitochondrial damage assay was conducted based on the am-
pliﬁcation of long mitochondrial DNA fragments [24]. Total DNA
was isolated from cerebella of WT and bella mice. Both a long
(10.1 kb) and a short mitochondrial fragment (117 bp) were am-
pliﬁed using the following primers: 10.1 kb fragment: 5′-GCC AGC
CTG ACC CAT AGC CAT AAT AT-3′ (forward); 5′-GCC AGC CTG ACC
CAT AGC CAT AAT AT-3′ (reverse) and 117 bp fragment: 5′-CCC AGC
TAC TAC CAT CAT TCA AGT-3′ (forward); 5′-GAT GGT TTG GGA GAT
TGG TTG ATG T-3′ (reverse). PCR for the long mitochondrial frag-
ment was carried out using La-Taq DNA polymerase (Takara) with
the following PCR conditions: Initial denaturation at 94 °C for
1 min, followed by 24 cycles of 94 °C for 30 s, 60 °C for 30 s and
72 °C for 20 min. PCR for the short mitochondrial fragment was
carried out using Taq DNA polymerase (Sigma-Aldrich) with the
following PCR conditions: Initial denaturation at 94 °C for 2 min,
followed by 35 cycles of 94 °C for 30 s, 56 °C for 30 s and 72 °C for
1 min. The amount of DNA before and after the PCR reactions was
quantiﬁed ﬂuorometrically using the PicoGreen dsDNA quantita-
tion reagent (Life Technologies). The ﬂuorescent signal was mea-
sured at excitation and emission wavelengths of 485 nm and
528 nm, respectively, using a FLUOstar Omega microplate reader
(BMG Labtech).
2.13. Mitochondrial complex activity assay
Complex I activity assay was conducted based a spectro-
photometric method modiﬁed from [25]. Firstly, 1 ml of Complex I
assay buffer (0.025 M potassium phosphate buffer, pH 7.2, 5 mM
MgCl2, 13 mM NADH, 65 mM coenzyme Q (Sigma-Aldrich), 0.25%
fatty-acid-free albumin, 3.6 μM Antimycin A (Sigma-Aldrich)) was
added to a cuvette and warmed to 30 °C. Then, 100 μg of mitochon-
dria were added and mixed with the Complex I assay buffer followed
by immediate measurement in a spectrophotometer (Shimadzu) at
340 nm at 30 °C for 3 min. As a control, mitochondrial samples were
treated with 10 μM rotenone after the initial measurement and
measured again at 340 nm at 30 °C for 3 min. The complex II activity
assay was measured by following the protocol as previously described
[26], with minor modiﬁcations. Firstly, 20 μg puriﬁed mitochondria
from mouse cerebella were incubated in a cuvette containing assay
buffer 1 (0.025 M potassium phosphate buffer, pH 7.2, 5 mM MgCl2,
2 mM sodium succinate (Sigma-Aldrich)) at 30 °C for 10 min. Then,
10 μl of buffer 2 (0.025 M potassium phosphate buffer, pH¼7.2,
600 mM rotenone, 360 mM antimycin A and 5 mM di-
chlorophenolindophenol (DCPIP, Sigma-Aldrich)) was added to the
cuvette and absorbance at 600 nm was immediately monitored in a
spectrophotometer (Shimadzu) for 1 min. Complex III activity was
monitored by measuring cytochrome c reduction at 550 nm essen-
tially as described in [27]. Prior to the assay, decylubiquinone was
reduced with sodium borohydride (NaBH4) to synthesise decylubi-
quinonol. 20 μg of mitochondria from each sample were incubated in
a cuvette of complex III assay buffer (50 mM potassium phosphate,
3 mM sodium azide (NaN3), 1.5 μM rotenone, 50 mM cytochrome c
(Sigma-Aldrich)). Then, decylubiquinol was added to the cuvette to
make a ﬁnal concentration of 50 mM. Reduction of cytochrome c was
read at 550 nm at 30 °C for 1 min. Complex IV activity was carried out
by measuring cytochrome c oxidation at 550 nm, a method modiﬁed
from Wharton et al. [28]. Brieﬂy, approximately 100 μg of mi-
tochondria were added and mixed with the Complex IV assay buffer
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phate buffer) followed by immediate measurement at 550 nm at
30 °C for 3 min. Citrate synthase activity was assayed by measuring
formation of nitrobenzoic acid (TNB) at 412 nm as a result of the
reaction between Coenzyme A (CoA-SH) and 5′, 5′-Dithiobis 2-ni-
trobenzoic acid (DTNB) [29]. In brief, 840 ml of water, 100 ml of assay
buffer (1 mM Dinitrobenzoic acid in 1 M Tris–HCl, pH¼8.1), 50 ml of
synthesised Acetyl CoA and 30 mg of mitochondria were added, mixed
and incubated at 30 °C for 5 min. After incubation, 50 ml of 10 mM
Oxaloacetate (Sigma-Aldrich) was added followed by immediate
measurement at 412 nm at 30 °C for 1 min.
2.14. Mitochondrial stress test
Mitochondrial stress testing was carried out using a Seahorse
Bioscience XF96 analyser (Seahorse Bioscience Inc.) in 96-well plates
at 37 °C as per the manufacturer's instructions with minor mod-
iﬁcations. Brieﬂy, GCs at P7 were seeded at 2105 cells/well one
week prior to the assay. On the test day, the growth media was re-
moved, washed once and replaced with XF assay media (Seahorse
Bioscience Inc.) and the plate was incubated in a CO2-free incubator
for 1 h at 37 °C. The hydrated cartridge sensor was loaded with ap-
propriate volume of mitochondrial inhibitors to achieve ﬁnal con-
centrations in each well: oligomycin (3 mM), carbonilcyanide p-tri-
ﬂouromethoxyphenylhydrazone (FCCP) (2 μM) and with rotenone/
antimycin A (both 2 mM). Then, levels of basal respiration, ATP pro-
duction, proton leak, maximal respiration and non-mitochondrial
respiration were measured as described in manufacturer's protocol.Fig. 1. Oxr1 isoforms display differential cellular localisation patterns. (A) A schematic ill
study: Oxr1 full-length (FL) at approximately 84 kDa, intermediate isoforms (INT) at appr
Total brain homogenate from wild-type mouse brain was blotted with anti-Oxr1 [9]. (B, C
mouse brain (B) and spinal cord (C) were subjected western blot analysis with anti-Oxr
(D) Mitochondria puriﬁed fromwild-type mouse cerebellar tissue were sub-fractionated
total mitochondrial sample (T) were subjected to western blotting using the anti-Oxr1 an
and Methods. Oxr1 is mainly detected in OM and IM fraction. (E) Mitochondria puriﬁ
trypsin prior to immunoblotting with mitochondrial marker proteins: TOM20 and VDAC
HSP-60 for MX. All wild-type tissue used was from male C3H/HeH mice at P56.2.15. Transmission Electron Microscopy (TEM)
Perfused brain tissue was prepared according to standard TEM
protocols [30]. Blocks were sectioned using a UC7 ultramicrotome
(Leica) and a Diatome diamond knife. Sections (90 nm) were post-
stained with lead citrate and imaged on a Tecnai 12 TEM (FEI)
operated at 120 kV. Digital images were acquired using a US1000
CCD camera (Gatan) and OneView (Gatan).
2.16. Statistical analysis
Results were analysed using GraphPad Prism software. Pairwise
analyses between wild-type and mutant or between the various
treatments were compared using a 1-way ANOVA with post-hoc
analysis or Student's t-test as indicated. P-values o0.05 were con-
sidered to be signiﬁcant. Data are expressed as the mean /þ S.E.M.3. Results
3.1. Different isoforms of Oxr1 are expressed in speciﬁc subcellular
compartments
Several isoforms of Oxr1 have been described to date in
mammalian cells, and evidence from cDNA cloning, qRT-PCR and
western blotting suggest that all of these contain the conserved
TLDc domain (Fig. 1A) [9,16]. However, the subcellular localisation
of these individual isoforms has not been investigated. To addressustration of four predicted Oxr1 isoforms in mouse detected by western blot in this
oximately 55 kDa and 40 kDa, and the shortest (C) isoform at approximately 24 kDa.
) Total tissue homogenate, cytoplasmic and mitochondrial fractions fromwild-type
1, anti-GAPDH as a cytoplasmic marker and anti-COX IV as a mitochondrial marker.
into OM, IMS, IM and MX by ultracentrifugation. Each sub-fraction in addition to the
tibody and speciﬁc markers for individual compartment as described in the Material
ed from wild-type mouse brain were incubated with increasing concentrations of
for the OM, cytochrome c (Cyt-C) and COX IV for the IMS and IM, respectively and
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mitochondrial fractions from wild-type mouse brain and spinal
cord were subjected to western blotting using an antibody against
an epitope in the TLDc domain of Oxr1 [9]. In total tissue lysate,
four main isoforms of Oxr1 are detected in mouse brain at ap-
proximately 84, 55, 40 and 24 kDa (Fig. 1A). Upon fractionation,
however, the shortest isoform (Oxr1-C, approximately 24 kDa) was
almost exclusively localised in the mitochondrial fraction from the
brain (Fig. 1B), while the full-length Oxr1 isoform (Oxr-FL, ap-
proximately 84 kDa) was localised in the cytosolic fraction. In
addition, the two intermediate isoforms were enriched in the
mitochondrial fraction. In the spinal cord, a similar distribution
was observed, although Oxr1-C could not be detected (Fig. 1C).
These data suggest that some, but not all, Oxr1 isoforms are lo-
calised to the mitochondria.
3.2. Mitochondrially localised Oxr1 is associated with mitochondrial
OM
We next studied the sub-mitochondrial localisation of Oxr1
using ultracentrifugation to separate the outer membrane (OM),
the intermembrane space (IMS), the inner membrane (IM) and the
matrix (MX) prior to immunoblotting. Interestingly, these data
indicate that the shorter isoforms of Oxr1 are localised in the
mitochondrial OM and IM, while only a very small proportion of
these isoforms was detected in the IMS and MX (Fig. 1D). In ad-
dition, the speciﬁcity of the sub-fractionation was conﬁrmed using
a set of speciﬁc markers (Fig. 1D). It is noted that the OM marker
voltage-dependent anion channel (VDAC) was also observed in the
IM, while the IM marker COX IV was also detected in the OM
fraction; this is likely due to incomplete OM/IM separation due to
multiple contact points between mitochondrial membranes as
previously described [21,31].
To further characterise the membrane-associated localisation of
Oxr1 within mitochondria, a trypsin susceptibility assay was
conducted using intact mitochondria puriﬁed from mouse brain
[21] (Fig. 1E). All Oxr1 isoforms were digested at the lowest (10 μg/
ml) trypsin concentration, apart from the 55 kDa isoform that
required 100 mg/ml (Fig. 1E). As a positive control, TOM20-a re-
ceptor loosely associated with the cytosolic side of the OM [32]-
was assayed in parallel, and this appeared to have poor resistance
to trypsinisation as expected. Conversely, VDAC and COX IV-
transmembrane proteins localised in OM and IM, respectively –
were not digested even in the presence of high concentration
(500 mg/ml) of typsin (Fig. 1E). Furthermore, cytochrome c and
HSP60-localised in IMS and MX, respectively – were also barely
affected (Fig. 1E). Taken together, these data suggest that the
shorter isoforms of Oxr1 are loosely associated with the outer
mitochondrial membrane, potentially facing towards the cytosol.
3.3. Over-expression of Oxr1 in the cytosol is more protective against
oxidative stress-induced cell death than mitochondrial over-
expression
We have shown previously that the Oxr1-C isoform, which
contains almost exclusively the TLDc domain, is capable of pre-
venting oxidative damage in vitro [9]. Indeed, this isoform appears
to be as potent an antioxidant as the full-length isoform (Oxr1-FL)
in neuronal cells [33], suggesting that the TLDc domain alone is
able to confer neuroprotection. It is noteworthy, however, that
these experiments have used a promoter that expressed the
cloned Oxr1-C protein in the cytoplasm [9]. Having demonstrated
here that non-full-length isoforms of Oxr1 are likely to be loosely
associated to the mitochondrial membrane, we therefore wished
to investigate whether cytoplasmic over-expression of this parti-
cular Oxr1-C isoform was more neuroprotective against OScompared to targeted over-expression in mitochondria, where is it
found endogenously. Cells were either transfected with Oxr1-C
containing a standard CMV promoter with an additional N-term-
inal mitochondrial localisation signal (MLS) (Oxr1-C-Mito), Oxr1-C
without an additional MLS tag (Oxr1-C-Cyto) or an empty negative
control vector. First, the sub-cellular localisation of each Oxr1-C
protein was conﬁrmed by co-immunostaining with appropriate
markers (Supplementary Figure 1A). In addition, the expected lo-
calisation of the tagged proteins was conﬁrmed by fractionation of
transfected cells and western blotting. (Supplementary Figure 1B).
To induce OS, cells were treated with hydrogen peroxide (H2O2)
and cell death was measured by quantifying cleaved caspase-3, a
marker of cell apoptosis, compared to untreated cells (Fig. 2A).
After treatment, cells transfected with the control vector showed
an increase in the proportion of cell death of approximately 80%
(Fig. 2B). In line with previous results, expression of the cyto-
plasmic Oxr1-C-Cyto construct was protective against cell death,
and after treatment there was only an approximately 20% increase
in cell death, signiﬁcantly lower than the control vector (Fig. 2B).
Interestingly, mitochondrial over-expression of Oxr1-C (Oxr1-C-
Mito) did not appear to show any protection against OS as the
percentage increase in cell death was similar to the control vector
(an approximately 90% increase) (Fig. 2B). This indicates that cy-
toplasmic over-expression of Oxr1-C is potentially more effective
at preventing OS-related cell death than mitochondrial over-
expression.
3.4. Cytoplasmic but not mitochondrial over-expression of Oxr1 al-
leviates mitochondrial morphological changes caused by acute rote-
none-induced oxidative stress
It is well-established that mitochondrial morphology is mod-
iﬁed in response to oxidative stress and that these changes can
subsequently affect mitochondrial function [34–36]. As Oxr1-C
was able to provide protection against OS, we wanted to further
understand the potential role of mitochondria in this process.
Therefore, we examined whether over-expressing Oxr1 prevents
mitochondrial morphological changes induced by OS. For these
experiments, we selected rotenone (50 mM for 1 h) as a speciﬁc
and potent inhibitor of mitochondrial complex I capable of causing
oxidative damage and mitochondrial morphological changes
[34,37,38]. Prior to treatment, cells were transfected with either an
empty vector, Oxr1-C-Cyto or Oxr1-C-Mito. We also added an
Oxr1-FL-Cyto construct to this experiment to complement our
other studies that have utilised successfully this full-length iso-
form as a protective protein in vivo [9,39] (Fig. 3A). Consistent with
previous ﬁndings [34], by quantifying mitochondria labelled with
COX IV, rotenone exposure caused a shift of mitochondrial shape
from mainly tubular, which is found in healthy non-treated cells,
to non-tubular (‘donut’ or ‘blob’ shape) (Fig. 3B); thus in cells
transfected with empty vector, the ratio between tubular and non-
tubular mitochondria was signiﬁcantly reduced by over 2-fold
after rotenone exposure (Fig. 3C). In cells over-expressing Oxr1-FL-
Cyto or Oxr1-C-Cyto, no signiﬁcant reduction of this ratio was
observed, suggesting a protective role of cytoplasmic Oxr1 against
mitochondrial morphological modiﬁcation induced by rotenone
(Fig. 3C). Interestingly, however, expression of the Oxr1-C-Mito
construct caused a shift towards non-tubular mitochondria, simi-
lar to that observed for cells transfected with an empty vector. In
addition, pair-wise comparisons showed that under rotenone
treatment, only cells over-expressing Oxr1-C-Cyto had a sig-
niﬁcantly higher proportion of tubular mitochondria compared to
control cells (Fig. 3C). Next, to exclude the possibility that these
ratios were confounded by a change in total number of mi-
tochondria after treatment, the total number of mitochondria per
focal plane was quantiﬁed, and no differences were observed
Fig. 2. Cytoplasmic over-expression of Oxr1 confers stronger protection against oxidative stress than mitochondrial over-expression. (A) Representative images of HeLa cells
transfected with the control vector (pcDNA3), Oxr1-C-Cyto or Oxr1-C-Mito in non-treated (NT) conditions or after H2O2 treatment (50 μM for 4 h). Cells were immunostained
with anti-myc (for Oxr1) or anti-cleaved caspase-3 (Casp3) to quantify apoptosis. Scale bar¼50 mm. (B) Cells expressing Oxr1-C-Cyto show stronger protection against
oxidative insult in comparison with cells expressing Oxr1-C-Mito or the pcDNA3 control vector. Data are shown 7SEM of 4 independent experimental repeats and analysed
by ANOVA followed by Bonferroni post-hoc tests, *po0.05, ***po0.001.
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results suggest that cytosolic over-expression of either Oxr1-FL or
Oxr1-C is more effective at alleviating mitochondrial morpholo-
gical changes caused by rotenone than over-expression of Oxr1-C
in mitochondria.
To further investigate these ﬁndings in relation to endogenous
Oxr1, we examined whether there would be a shift in the ratio
between the mitochondrial and cytoplasmic distribution of Oxr1during OS. N2a cells were subjected to a timecourse of H2O2
treatment, followed by fractionation and western blotting. N2a
cells express all the Oxr1 isoforms found in mouse brain and these
data show the expected presence of the shortest isoform
(24 kDa, Oxr1-C) in the mitochondria and the longest (Oxr1-FL)
in the cytoplasm (Supplementary Figure 2A). Speciﬁcally, quanti-
ﬁcation of the shortest isoform revealed there was a trend towards
a reduction in mitochondrial expression levels after OS, yet this
Fig. 3. Cytoplasmic over-expression of Oxr1 alleviates mitochondrial morphological changes induced by acute rotenone treatment. (A) Representative images showing HeLa
cells transfected with the control vector, Oxr1-FL-Cyto, Oxr1-C-Cyto or Oxr1-C-Mito, in non-treated (NT) conditions or under rotenone treatment (50 μM, 1 h) conditions;
Cells were immunostained with anti-myc (for Oxr1) and anti-COX IV antibodies. Scale bar¼20 mm. (B) Representative images showing tubular mitochondria in untreated
control cells (arrows), while non-tubular (donut/blob) mitochondria become predominant after rotenone treatment (arrowheads). Scale bar¼10 mm. (C) Ratio of mi-
tochondria classiﬁed as tubular versus non-tubular before and after rotenone treatment. Rotenone treatment signiﬁcantly reduced the ratio of tubular to non-tubular
mitochondria, but over-expression of cytoplasmic Oxr1 prevented this reduction. (D) The total number of mitochondria per focal plane remains unchanged after rotenone
treatment. Data are shown as the mean7SEM from 3 independent replicates of each genotype. A minimum of 15 cells were analysed per group in each repeat. Data are
shown as mean7SEM and were analysed by ANOVA followed by Bonferroni post-hoc tests; *po0.05, **po0.01.
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speciﬁc isoform in the cytoplasmic fraction, even up to 2 h after
H2O2 treatment (Supplementary Figure 2B). In addition, the ex-
pression of other Oxr1 isoforms did not signiﬁcantly alter under
OS. These data suggest that there is no overt shift in the sub-cel-
lular distribution of Oxr1 from the mitochondria to the cytoplasm
under these OS conditions.
3.5. Mitochondrial length is reduced in primary cerebellar GCs from
mice lacking Oxr1
Our data suggest that over-expressing cytosolic Oxr1 in vitro is
able to alleviate OS-induced mitochondrial morphological chan-
ges; thus we speculated that the complete loss of Oxr1 would in-
ﬂuence mitochondrial structural integrity or function. To examine
this hypothesis, we ultilised primary cerebellar GC neurons from
the homozygous bella mutant mouse (Oxr1bel/bel), that does not
express Oxr1 due to deletion of the entire genomic locus [9].Cerebellar GCs are the only region of the brain where neurode-
generation is detected at disease end-stage in bella mutants, sug-
gesting that these particular cells are more susceptible to deletion
of Oxr1 than other neuronal populations. Primary GCs for these
experiments from bella mice and wild-type (WT) littermate con-
trols at P7 were isolated and grown in vitro for 7 days (DIV7) and
their identity conﬁrmed with GC marker GABA(A) receptor subunit
alpha-6 (GABRA6) (Supplementary Figure 3). By quantiﬁcation of
mitochondrial structure between the two genotypes, we dis-
covered that mitochondrial length was signiﬁcantly reduced in
primary GCs of bella mice in comparison with WT (Fig. 4A and B).
Importantly, there was neither a difference in average size or total
number of mitochondria per focal plane between the genotypes
(Fig. 4C and D); these data suggest that the mitochondrial popu-
lation shifts towards a more non-tubular structure when Oxr1 is
deleted. Thus to begin to test whether loss of Oxr1 can lead to
modiﬁcations in mitochondrial ultrastructure in vivo, transmission
electron microscopy (TEM) using ultra-thin sections was
Fig. 4. Mitochondrial morphological changes in primary cerebellar GCs of bella mice. (A) Representative images showing mitochondria in wild-type (WT) and bella (bel)
primary cerebellar GCs. Scale bars ¼ 10 mm. (B) Mitochondrial length (example arrows in (A)) is signiﬁcantly reduced in bella compared to WT GCs. (C and D) No difference
was observed in the average size or total number of mitochondria per focal plane between WT and bella GCs. Mitochondria were quantiﬁed in primary GCs of 3 WT and 3
bella mice and a minimum of 10 cells were analysed per replicate. Data are shown as mean7SEM and analysed by Student's t-test; *po0.05.
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bella and age-matched WT mice. Mitochondria from multiple re-
gions in the GC layer were assessed, and both genotypes displayed
normal and comparable mitochondrial morphology (Supplemen-
tary Figure 4). Taken together, these results suggested that dele-
tion of Oxr1 in mice can alter the gross morphology of mi-
tochondria towards a shape indicative of OS, but does not cause
any overt abnormalities in ultrastructure in vivo.
3.6. Deletion of Oxr1 inﬂuences expression of mitochondrial ﬁssion
regulators
Since mitochondrial shape and morphology are regulated by
fusion and ﬁssion [40], we examined next whether deletion of
Oxr1 affects these processes. Protein levels of major known fusion
regulators, Mfn1, Mfn2 and OPA1 as well as ﬁssion mediators Drp1
and Fis1 were quantiﬁed from WT and bella cerebellar homo-
genates taken at P22 (Fig. 5A). No differences in expression were
detected between genotypes, with the exception of Drp1, that
showed a small but statistically signiﬁcant increase in bella mice
compared to WT (Fig. 5B). Under OS, Drp1 is phosphorylated at
Ser616, which activates the protein for recruitment to mitochon-
dria to facilitate the ﬁssion process; conversely, dephosphorylation
at Ser616 inhibits mitochondrial ﬁssion [41,42]. We hypothesised
that there may be an inhibitory effect on the activity of Drp1 in
mutant mice, thus we tested the level of phospho-(p-)Drp1 S616
(Fig. 5C). Interestingly, the level of p-Drp1 S616 was signiﬁcantly
lower in cerebella homogenate from bella compared to WT mice
(Fig. 5D), indicating an inhibitory effect of Drp1's activity. Overall,
these data suggest that the change in mitochondrial morphologyobserved in bella mice may be caused by a compensatory pathway
that inhibits the activity of Drp1 through dephosphorylation of
Ser616 in response to stress caused by the deletion of Oxr1.
3.7. Deletion of Oxr1 does not affect mitochondrial DNA integrity or
ETC protein activity
The vulnerability of mitochondrial (mt)DNA to OS has been
well-established [43,44] and recently, accumulation of mtDNA
damage was found in OXR1 depleted (approximately 85% knock-
down) HeLa cells treated with H2O2 [10]. Furthermore, we have
shown previously that OS-induced DNA damage occurs in the
cerebellar GC layer of end-stage bella mice [9]. To study next
whether the deletion of Oxr1 can cause accumulation of en-
dogenous mtDNA lesions in in vivo, DNA was extracted from the
cerebellum of WT and end-stage (P22) bella mice and the mtDNA
was subjected to quantitative (q)PCR (Fig. 6A). Using this method,
no increase in mtDNA lesions was evident in the bella cerebellum
compared to WT (Fig. 6B).
Previous discoveries have suggested an association between
mitochondrial oxidative phosphorylation (OXPHOS) abnormalities
and neurodegenerative disease [45]. Therefore, to examine whe-
ther the neurodegeneration observed in bella mice is related to
such defects, we ﬁrst examined ETC complex protein expression
and assembly. Initially, the expression level of ﬁve ETC complex
subunits (Complex (C) I to V) in both WT and bella mice were
measured simultaneously by western blot and no difference in
between genotypes was observed (Supplementary Figure 5). We
then tested whether loss of Oxr1 had an impact on mitochondrial
complex assembly pathways by conducting Blue Native (BN) PAGE
Fig. 5. Expression level of mitochondrial fusion and ﬁssion proteins in the cerebellum of WT and bellamice. (A) Cerebellar homogenates from end-stage (P22) bella (bel) and
age-matched wild-type (WT) mice were subjected to western blotting analysis for mediators of mitochondrial ﬁssion (Drp1 and Fis1) and fusion (Mfn1, Mfn2 and Opa1).
(B) Quantitative analysis by densitometry; the total level of Drp1 is signiﬁcantly higher in bella compared to WT tissue. (C) Western blot of cerebellar homogenate from end-
stage bella and age-matched WT mice probed for p-Drp S616, indicating that the expression level in bella is signiﬁcantly lower than WT (D). Data are shown as mean7SEM
from 3–6 independent samples of each genotype and were analysed by Student's t-test; *po0.05.
Fig. 6. No evidence for mtDNA damage or mitochondrial complex assembly defects in bella mice. (A) Representative gel images showing PCR products of long (10.1 kb) and
short (117 bp) mtDNA fragments from total DNA extracted from cerebellar tissue of end-stage bella (bel) and age-matched WT mice. (B) Quantiﬁcation of mtDNA (long
fragment) was carried out using the PicoGreen method by normalisation to the short mtDNA fragment. Data are shown as the mean 7 SEM from 5–6 replicate samples of
each genotype and analysed by Student's t-test. (C) End-stage bella and age-matched WT cerebellar tissue were subjected to BN-PAGE analysis to resolve puriﬁed mi-
tochondrial proteins solubilized by the detergent n-dodecyl-β-D-maltopyranoside (DDM). A representative image is shown of samples probed using an anti-OxPhos Complex
antibody indicating no defects in complex assembly in bella mice.
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Fig. 7. Oxygen consumption in primary GCs is not affected by deletion of Oxr1.
(A) Oxygen consumption rate (OCR) proﬁles are expressed as pmol of oxygen
consumed per minute in primary GCs of wild-type (WT) and bella (bel) mice. Ar-
rows indicate when mitochondrial inhibitors/stressors were added to the assay:
oligomycin (3 mM), FCCP (2 mM) and rotenone and antimycin (2 mM, each).
(B) Normalised OCRs after subtraction of rotenone/antimycin treated OCR (non-
mitochondrial respiration), under basal condition, after adding oligomycin (3 mM,
proton leak) or FCCP (2 mM, maximal respiration). The data were obtained from
Y. Wu et al. / Free Radical Biology and Medicine 95 (2016) 255–267264analysis to detect formation of the ﬁve ETC complexes from cer-
ebellar tissue. These data also revealed no difference between WT
and bella mice (Fig. 6C). In addition, the mitochondrial ETC com-
plex activities of intact mitochondrial extracts from the cerebella
of end-stage bella and age-matched WT mice were measured.
However, no difference in CI, CII, CIII, CIV or citric synthase activity
was observed between genotypes (Supplementary Figure 6).
3.8. Primary cerebellar GCs from bella mice display normal mi-
tochondrial metabolism
To date, loss or disruption of a number of antioxidant proteins
has been found to inﬂuence mitochondrial oxygen consumption as
part of a potential neurodegenerative pathway [46,47]. We
therefore studied whether deletion of Oxr1 can cause similar de-
fects by measuring mitochondrial oxygen consumption and other
respiratory parameters from WT and bella primary GCs cultured
for 7 days. Basal respiration level was ﬁrst measured prior to ad-
dition of any mitochondrial stressors, and no difference was ob-
served between genotypes (Fig. 7A). After adding the mitochon-
drial complex V inhibitor oligomycin, a marked decline of oxygen
consumption level (approximately 100 pmol/min) was observed in
both WT and bella GCs, indicating the same amount of oxygen was
used for ATP production. Next the mitochondrial uncoupler FCCP
was added, triggering a marked induction of oxygen consumption
(approximately 150 pmol/min) in both WT and bella, suggesting
the spare oxygen consumption capacity of GCs from both geno-
types was equivalent (Fig. 7A). Finally, rotenone and antimycin A,
which inhibit CI and CIII respectively, were added to the assays
resulting in a considerable reduction in oxygen consumption as
expected. The remaining oxygen consumption level indicated the
amount of oxygen available for non-mitochondrial respiration, at
approximately 50 pmol/min for both genotypes. By subtracting the
non-mitochondrial oxygen consumption level, the normalised
data suggest that there was no signiﬁcant difference of mi-
tochondrial oxygen consumption in basal level, proton leak stage
or maximum respiration between WT and bella GCs (Fig. 7B).3 independent experiments using primary GCs obtained from 6 WT and 5 bella
mice. Data are shown as the mean7SEM.4. Discussion
In this study we have demonstrated that Oxr1 is expressed in
an isoform-speciﬁc pattern in mitochondria and that the expres-
sion levels of this novel antioxidant protein are likely to play a role
in regulating aspects of mitochondrial morphology in the presence
of OS.
Several isoforms of OXR1 and its orthologues have been de-
scribed in mammalian and non-mammalian systems [7,19,48], and
western blot results have indicated a complex differential dis-
tribution of isoforms in mouse tissue [9,13]. Here, we reveal the
cytosolic localisation of the longest Oxr1-FL (84 kDa) isoform and
mitochondrial enrichment for the shorter isoforms (55, 40 and
24 kDa) based on our antibody raised against a shared C-terminal
epitope. These ﬁndings suggest that the mitochondrial localisation
and induction of OXR1 observed previously in mammalian cells
may have originated from non-full-length isoforms [9,19]. In ad-
dition, using a combination of ultracentrifugation and trypsin di-
gestion assays, our data suggest that that Oxr1 is not likely to be
present in the mitochondrial matrix but is found at the mi-
tochondrial OM, facing the cytosol. It is still unclear, however, how
Oxr1 is translocated to this position. It has been postulated that a
mitochondrial localisation signal (MLS) is present at the N-termi-
nus of Oxr1 in yeast (scOxr1) [19], yet no such region is present in
any of the known isoforms of OXR1 in mouse or human. Indeed, in
our study, while tagged mouse Oxr1 proteins with an additional
MLS are successfully targeted to mitochondria (Oxr1-C-Mito),over-expression of constructs with no additional MLS (both Oxr1-
C-Cyto and Oxr1-FL-Cyto) are not mitochondrially localised. In-
terestingly, we were also unable to target the full-length Oxr1
protein into mitochondria using the same N-terminal MLS (data
not shown). These ﬁndings are thus consistent with a transient
association between Oxr1 and mitochondria that may be size-se-
lective. Of note, the anti-oxidative protein DJ-1, mutated in familial
Parkinson's disease, has a similar OM-associated localisation, de-
spite lacking a bona ﬁde MLS [49–52]. Translocation of DJ-1 into
mitochondria is thought to be mediated by interacting with cha-
perones including heat-shock protein (HSP) 70, C-terminus of
heat-shock cognate 71 kDa protein (HSC70)-Interacting Protein
(CHIP) and mtHsp70/Grp75 [24]. It is possible that the transloca-
tion of Oxr1 to mitochondria occurs via a similar mechanism; for
example, our initial results from a protein interaction screen
suggest that under OS, Oxr1-C may interact with DNAJC19 [13], a
mitochondrial protein translocase component [53]. Further studies
will be required to conﬁrm such associations and understand their
functional relevance to OS sensitivity.
Our cell survival assays revealed that cytoplasmic expression of
the shortest Oxr1 isoform (Oxr1-C-Cyto), containing almost ex-
clusively the TLDc domain, is protective against OS-induced
apoptosis; this is consistent with previous ﬁndings that the TLDc
domain of Oxr1 is a key feature of its anti-oxidative role [9,33].
Interestingly, more effective protection against OS-induced apop-
tosis was conferred by over-expressing Oxr1-C in the cytoplasm
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Importantly, the MLS used here was from subunit VIII of human
cytochrome c oxidase that targets proteins to the mitochondrial
matrix [22]; thus our ﬁndings suggesting that a subtle balance
between cytosolic and mitochondrial OM localisation may be re-
quired for the anti-oxidative role of Oxr1 in these assays. Inter-
actions of various pro- and anti-apoptotic proteins as well as ROS
sensors occur at the interface between the cytosol and the mi-
tochondrial OM, and these binding events are thought to mediate
mitochondrial OM permeabilisation (MOMP) one of the hallmarks
of the early stage of apoptosis [54]. Moreover, regulation of MOMP
is independent from IM and MX proteins [55]. Hence, it will be
worthwhile to determine whether the OM-associated, cytosolic-
facing Oxr1 isoforms establish their anti-oxidative role via these
pathways.
Interestingly, we did not see an induction or signiﬁcant shift in
the subcellular re-localisation of Oxr1 isoforms in N2a cells under
OS. Previous data have indicated that certain isoforms of OXR1 can
be induced under stress at the protein level [19]; yet other studies
indicate that this response may be transient and cell-type speciﬁc,
as shown by temporal, isoform-speciﬁc induction [13,33] or a lack
of induction [33,56] at the RNA level under OS. The fact that nei-
ther the shortest or longest OXR1 isoforms lack a predicted or
experimentally determined antioxidant response element (ARE),
supports the notion that the gene is not downstream of classical
Nrf2-mediated OS-response pathways [57,58]; however, further
work is needed to determine the complexities of the timing and
functional signiﬁcance of endogenous Oxr1 induction to cellular
survival.
In an earlier study, Elliot et al. over-expressed human OXR1
with an additional MLS in a mutant strain of yeast that is sensitive
to H2O2-induced lethality and their data suggested that mi-
tochondrial localisation of OXR1 is required for protection against
OS [19]. The apparent discrepancy between these results and our
new study may relate to differences in the type of assay or species
used, the levels of over-expression achieved, or the type of MLS
used to tag OXR1 itself; although Elliot et al. used a MLS from yeast
Sod2 that should also direct proteins to the mitochondrial matrix.
The particular isoforms of Oxr1 used in such OS protection assays
must also be considered. We have focused here on the shortest
Oxr1-C isoform that is based on a known cDNA that is expressed in
mouse and humans [9] that we have also shown to be neuropro-
tective [9,33]. Whereas other studies have used longer isoforms
containing additional exons outside of the TLDc domain – likely to
be represented by the 44 and/or 55 kDa proteins we see by wes-
tern blot – that may also play an important role in OS resistance
[16].
Oxr1-related proteins localised to other cellular compartments
may also confer protection against OS-related insults; for instance
over-expression of Oxr1 from the silk-worm Bombyx mori
(BmOxr1) was protective against OS in Drosophila melanogaster
[12]. Interestingly, when over-expressed, BmOxr1 was found
mainly in the nuclei of Drosophila melanogaster cells. The sequence
alignments provided suggest that this BmOXR1 protein has se-
quence identity with NCOA7, a known nuclear-expressed TLDc
domain-containing protein that is also able to confer protection
against OS [8].
Mitochondrial morphological changes caused by rotenone have
been demonstrated to be OS-related [34]. We show here that over-
expression of Oxr1 in the cytoplasm is capable of preventing the
mitochondrial morphological changes induced by rotenone, while
a reduction of mitochondrial length is observed in primary GCs
lacking Oxr1. These data are in line with our recent observations
that Oxr1 can prevent mitochondrial morphology defects caused
by ALS-associated Tdp-43 mutations [13]. Taken together, these
studies further suggest that Oxr1 is involved in maintainingmitochondrial morphology in the stress response as part of its
antioxidant function. Mitochondrial morphology is intensively
regulated by fusion and ﬁssion processes [40] and multiple lines of
evidence have shown that under OS, once phosphorylated at
Ser616, the ﬁssion protein Drp1 is activated to facilitate mi-
tochondrial fragmentation [41,59]. Based on our data from pri-
mary cells, we hypothesised that we might observe a similar shift
in the mitochondrial population towards a more pro-ﬁssion status
in cerebellar tissue of end-stage bella mice. Unexpectedly, how-
ever, the level of p-Drp1 (Ser616) was found to be reduced sig-
niﬁcantly in bella cerebellar tissue compared to WT. This could be
a result of a compensatory effect of Drp1 phosphorylation due to
cellular stress; indeed, a reduction of p-Drp1 S616 is also observed
in cells upon starvation [60].
As we observed mitochondrial structural changes in cells lacking
Oxr1, we also examined whether any other hallmarks of mi-
tochondrial dysfunction could be detected. No defects in oxygen
consumption or other respiratory measures were identiﬁed in pri-
mary GCs from bella mice, and there was no evidence for mtDNA
damage or ultrastructural abnormalities in cerebellar tissue from
the same mutants. Since our previous results show that only a small
percentage of neurons in the cerebellar granule cell layer are af-
fected in end-stage bella mutants [9], our data presented here may
reﬂect that overall mitochondrial functional differences in a large
population of cells or tissue lacking Oxr1 are simply below the de-
tection threshold of even sensitive quantitative assays. Moreover,
several lines of evidence indicate that the function of OXR1 be-
comes more critical, or key protective pathways become activated,
under OS conditions. For example, an increase in mtDNA damage
was observed previously in OXR1 knockdown cells, although exo-
genous OS was required to exacerbate this effect [10]. In addition,
an recent RNA-seq study in the same HeLa cell model revealed
additional cell death-response pathways were activated when OXR1
knockdown and OS were combined [56].5. Conclusions
In summary, our study reveals the detailed sub-cellular and
sub-mitochondrial localisation patterns of Oxr1 isoforms and
proposes that this protein plays a role in modulating mitochon-
drial morphology. In recent years, delivering antioxidant proteins
has been considered as a potentially effective way of treating
disease where OS is thought to be an important contributing factor
to pathology [61,62]. Indeed, targeting OXR1 to mouse kidney has
been shown to be protective against experimentally-induced renal
injury and inﬂammation [61] and mutations in an Oxr1 homologue
in Drosophila melanogaster show increased tolerance to Vibrio
cholerae infection [63]. Our ﬁndings deepen the understanding of
Oxr1 as a novel antioxidant protein and offer new and important
insights into its role in the OS-response and its potential use in
future antioxidant therapies.Acknowledgements
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